title: Melatonin: A Potential Anti-Oxidant Therapeutic Agent for Mitochondrial Dysfunctions and Related Disorders.
abstract: Mitochondria play a central role in cellular physiology. Besides their classic function of energy metabolism, mitochondria are involved in multiple cell functions, including energy distribution through the cell, energy/heat modulation, regulation of reactive oxygen species (ROS), calcium homeostasis, and control of apoptosis. Simultaneously, mitochondria are the main producer and target of ROS with the result that multiple mitochondrial diseases are related to ROS-induced mitochondrial injuries. Increased free radical generation, enhanced mitochondrial inducible nitric oxide synthase (iNOS) activity, enhanced nitric oxide (NO) production, decreased respiratory complex activity, impaired electron transport system, and opening of mitochondrial permeability transition pores have all been suggested as factors responsible for impaired mitochondrial function. Because of these, neurodegenerative diseases, such as Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), and aging, are caused by ROS-induced mitochondrial dysfunctions. Melatonin, the major hormone of the pineal gland, also acts as an anti-oxidant and as a regulator of mitochondrial bioenergetic function. Melatonin is selectively taken up by mitochondrial membranes, a function not shared by other anti-oxidants, and thus has emerged as a major potential therapeutic tool for treating neurodegenerative disorders. Multiple in vitro and in vivo experiments have shown the protective role of melatonin for preventing oxidative stress-induced mitochondrial dysfunction seen in experimental models of PD, AD, and HD. With these functions in mind, this article reviews the protective role of melatonin with mechanistic insights against mitochondrial diseases and suggests new avenues for safe and effective treatment modalities against these devastating neurodegenerative diseases. Future insights are also discussed.
authors.affiliation: 1 Department of Clinical Biochemistry, University of Kashmir Srinagar , India .
authors.forename: Showkat Ahmad
authors.initials: SA
authors.lastname: Ganie
authors.affiliation: 1 Department of Clinical Biochemistry, University of Kashmir Srinagar , India .
authors.forename: Tanveer Ali
authors.initials: TA
authors.lastname: Dar
authors.affiliation: 1 Department of Clinical Biochemistry, University of Kashmir Srinagar , India .
authors.forename: Aashiq Hussain
authors.initials: AH
authors.lastname: Bhat
authors.affiliation: 1 Department of Clinical Biochemistry, University of Kashmir Srinagar , India .
authors.forename: Khalid B
authors.initials: KB
authors.lastname: Dar
authors.affiliation: 1 Department of Clinical Biochemistry, University of Kashmir Srinagar , India .
authors.forename: Suhail
authors.initials: S
authors.lastname: Anees
authors.affiliation: 2 Department of Biochemistry, University of Kashmir Srinagar , India .
authors.forename: Mohammad Afzal
authors.initials: MA
authors.lastname: Zargar
authors.affiliation: 2 Department of Biochemistry, University of Kashmir Srinagar , India .
authors.forename: Akbar
authors.initials: A
authors.lastname: Masood
mesh_terms: D000375:Aging / Q000187:drug effects / Q000473:pathology; D000975:Antioxidants / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008550:Melatonin / Q000494:pharmacology / Q000627:therapeutic use*; D055442:Metabolome / Q000187:drug effects; D028361:Mitochondrial Diseases / Q000188:drug therapy* / Q000473:pathology; D018384:Oxidative Stress / Q000187:drug effects
chemical_list: D000975:Antioxidants; D008550:Melatonin